$66.935
1.365[2.08%]
Last update: 2:15PM Get Real Time Here
Cytokinetics
(NASDAQ:CYTK)Cytokinetics Stock (NASDAQ:CYTK), Analyst Ratings, Price Targets, Predictions
Cytokinetics Inc has a consensus price target of $72.54, established from looking at the 76 latest analyst ratings. The last 3 analyst ratings were released from Needham, Truist Securities, and JP Morgan on April 9, 2024, April 8, 2024, and March 7, 2024. With an average price target of $90.33 between Needham, Truist Securities, and JP Morgan, there's an implied 36.87% upside for Cytokinetics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Needham
Truist Securities
JP Morgan
Mizuho
Oppenheimer
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Cytokinetics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/09/2024 | CYTK | Buy Now | Cytokinetics | $66.00 | 63.64% | Needham | Serge Belanger | → $108 | Reiterates | Buy → Buy | Get Alert |
| 04/08/2024 | CYTK | Buy Now | Cytokinetics | $66.00 | 30.3% | Truist Securities | Srikripa Devarakonda | $86 → $86 | Reiterates | Buy → Buy | Get Alert |
| 03/07/2024 | CYTK | Buy Now | Cytokinetics | $66.00 | 16.67% | JP Morgan | Tessa Romero | $78 → $77 | Maintains | Overweight | Get Alert |
| 03/06/2024 | CYTK | Buy Now | Cytokinetics | $66.00 | 50% | Mizuho | Salim Syed | $103 → $99 | Maintains | Buy | Get Alert |
| 03/04/2024 | CYTK | Buy Now | Cytokinetics | $66.00 | 62.12% | Oppenheimer | Justin Kim | → $107 | Reiterates | Outperform → Outperform | Get Alert |
| 02/28/2024 | CYTK | Buy Now | Cytokinetics | $66.00 | 42.42% | HC Wainwright & Co. | Joseph Pantginis | → $94 | Reiterates | Buy → Buy | Get Alert |
| 02/28/2024 | CYTK | Buy Now | Cytokinetics | $66.00 | 63.64% | Needham | Serge Belanger | → $108 | Reiterates | Buy → Buy | Get Alert |
| 01/24/2024 | CYTK | Buy Now | Cytokinetics | $66.00 | 39.39% | UBS | Ashwani Verma | $61 → $92 | Downgrade | Buy → Neutral | Get Alert |
| 01/22/2024 | CYTK | Buy Now | Cytokinetics | $66.00 | 56.06% | Mizuho | Salim Syed | $80 → $103 | Maintains | Buy | Get Alert |
| 01/05/2024 | CYTK | Buy Now | Cytokinetics | $66.00 | 36.36% | Morgan Stanley | Jeffrey Hung | $60 → $90 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 12/28/2023 | CYTK | Buy Now | Cytokinetics | $66.00 | 30.3% | Truist Securities | Srikripa Devarakonda | $60 → $86 | Maintains | Buy | Get Alert |
| 12/28/2023 | CYTK | Buy Now | Cytokinetics | $66.00 | 39.39% | Raymond James | Sean McCutcheon | $63 → $92 | Maintains | Outperform | Get Alert |
| 12/27/2023 | CYTK | Buy Now | Cytokinetics | $66.00 | 63.64% | Needham | Serge Belanger | $60 → $108 | Maintains | Buy | Get Alert |
| 12/27/2023 | CYTK | Buy Now | Cytokinetics | $66.00 | 42.42% | HC Wainwright & Co. | Joseph Pantginis | $58 → $94 | Maintains | Buy | Get Alert |
| 11/09/2023 | CYTK | Buy Now | Cytokinetics | $66.00 | -24.24% | Goldman Sachs | Paul Choi | → $50 | Initiates | → Buy | Get Alert |
| 11/07/2023 | CYTK | Buy Now | Cytokinetics | $66.00 | — | B. Riley Securities | Mayank Mamtani | → $66 | Initiates | → Buy | Get Alert |
| 11/01/2023 | CYTK | Buy Now | Cytokinetics | $66.00 | -12.12% | HC Wainwright & Co. | Joseph Pantginis | → $58 | Reiterates | Buy → Buy | Get Alert |
| 10/20/2023 | CYTK | Buy Now | Cytokinetics | $66.00 | -12.12% | HC Wainwright & Co. | Joseph Pantginis | $49 → $58 | Maintains | Buy | Get Alert |
| 10/20/2023 | CYTK | Buy Now | Cytokinetics | $66.00 | -9.09% | Needham | Serge Belanger | → $60 | Reiterates | Buy → Buy | Get Alert |
FAQ
What is the target price for Cytokinetics (CYTK)?
The latest price target for Cytokinetics (NASDAQ: CYTK) was reported by Needham on April 9, 2024. The analyst firm set a price target for $108.00 expecting CYTK to rise to within 12 months (a possible 61.35% upside). 34 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cytokinetics (CYTK)?
The latest analyst rating for Cytokinetics (NASDAQ: CYTK) was provided by Needham, and Cytokinetics reiterated their buy rating.
When was the last upgrade for Cytokinetics (CYTK)?
There is no last upgrade for Cytokinetics.
When was the last downgrade for Cytokinetics (CYTK)?
The last downgrade for Cytokinetics Inc happened on January 24, 2024 when UBS changed their price target from $61 to $92 for Cytokinetics Inc.
When is the next analyst rating going to be posted or updated for Cytokinetics (CYTK)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cytokinetics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cytokinetics was filed on April 9, 2024 so you should expect the next rating to be made available sometime around April 9, 2025.
Is the Analyst Rating Cytokinetics (CYTK) correct?
While ratings are subjective and will change, the latest Cytokinetics (CYTK) rating was a reiterated with a price target of $0.00 to $108.00. The current price Cytokinetics (CYTK) is trading at is $66.94, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.